
|Videos|August 26, 2021
Part 2: Practical Considerations For Venetoclax in AML
Expert continues discussion on important considerations for the optimal use if venetoclax in patients with AML, such as CYP3A4 and p-glycoprotein drug interactions.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Reformulated Ranitidine After 5-Year Absence
2
FDA Approves Gene Replacement Therapy Itvisma for Patients With Spinal Muscular Atrophy
3
Gluteus Maximus Muscle Shape Changes Tied to Aging, Frailty, and Type 2 Diabetes
4
Update on Novel Antimicrobials and Their Uses
5

















































































































































































































